<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A"><gtr:id>5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A</gtr:id><gtr:name>Aston University</gtr:name><gtr:department>Sch of Life and Health Sciences</gtr:department><gtr:address><gtr:line1>Aston Triangle</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B4 7ET</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A"><gtr:id>5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A</gtr:id><gtr:name>Aston University</gtr:name><gtr:address><gtr:line1>Aston Triangle</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B4 7ET</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/938B0269-F28D-45D8-B660-22A0CB6254DF"><gtr:id>938B0269-F28D-45D8-B660-22A0CB6254DF</gtr:id><gtr:firstName>Roslyn</gtr:firstName><gtr:surname>Bill</gtr:surname><gtr:orcidId>0000-0003-1331-0852</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=DT%2FF00270X%2F1"><gtr:id>9FB66FC5-7630-4326-B359-0AB42E06FE82</gtr:id><gtr:title>The expression, modification and enhancement of protein therapeutics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>DT/F00270X/1</gtr:grantReference><gtr:abstractText>Site directed modification by both homogeneous glycosylation and pegylation has hitherto been unavailable in drug development and offers a major innovative advance to patients and carers alike. Such control of protein modifications by this consortium will for the first time bring the opportunity for clear structural control to produce the maximum therapeutic effect required. The consortium will use the additional funding provided by a successful application to develop better therapeutic glycoproteins. The expression of aglycosyl proteins in high yielding yeast systems will provide the protein backbone from which novel synthetic glycoproteins will be constructed. Synthetic glycans will be used to improve glycosylation and enhance pharmacokinetic properties. The application of a novel targeted pegylation technology will improve uniformity of pegylation as well as improve protein potency.</gtr:abstractText><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2008-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>191418</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings were used within Glycoform Ltd for business development. Glycoform co-funded a BBSRC CASE studentship as a consequence of the outputs of this grant.</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>99A91CE5-CE02-4FBE-BB1B-99ECB1CF8B37</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>544798eb633172.33241769</gtr:outcomeId><gtr:sector>Manufacturing, including Industrial Biotechology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>During the project we developed improved protein expression systems for human erythropoietin and selected mutants.</gtr:description><gtr:grantRef>DT/F00270X/1</gtr:grantRef><gtr:id>4573E415-10EC-443D-A295-D3901EF03EE9</gtr:id><gtr:impact>Not applicable</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-6935913271.2110077666e488</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Protein Expression System</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>We were able to produce a human protein in yeast cells and provide it in a form that could be modified by the company partners so that the protein could be used as a drug.</gtr:description><gtr:exploitationPathways>The findings are relevant to the production of a range of biopharamaceuticals as described in a recent review: http://journal.frontiersin.org/Journal/10.3389/fmicb.2014.00085/full</gtr:exploitationPathways><gtr:id>69F94F3E-17D4-4C80-AF87-064A95ACC016</gtr:id><gtr:outcomeId>5447b518ddd990.87244687</gtr:outcomeId><gtr:sectors><gtr:sector>Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://journal.frontiersin.org/Journal/10.3389/fmicb.2014.00085/full</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AB7D3F53-549C-40A0-861C-B1261637C702</gtr:id><gtr:title>Understanding the yeast host cell response to recombinant membrane protein production.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f47e95f70e70409d028c26146696bb9"><gtr:id>7f47e95f70e70409d028c26146696bb9</gtr:id><gtr:otherNames>Bawa Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>54479580047e44.32082524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C028109-6811-45E6-A83F-83F9FD1EBAD4</gtr:id><gtr:title>The effect of antifoam on recombinant protein production experiments in yeast: correlation of increased yield with improved secretion</gtr:title><gtr:parentPublicationTitle>Microbial Cell Factories</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66fbf5f3cd42f9b6db1e83f393582a95"><gtr:id>66fbf5f3cd42f9b6db1e83f393582a95</gtr:id><gtr:otherNames>S Routledge</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>m_762344945113910e66</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86E8BBC0-0AC4-4EF0-B796-73EFCB14F011</gtr:id><gtr:title>The implementation of a design of experiments strategy to increase recombinant protein yields in yeast (review).</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee13b43105d902f6c16e5e228c753a1"><gtr:id>bee13b43105d902f6c16e5e228c753a1</gtr:id><gtr:otherNames>Bora N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5447957fc51ab8.44016854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42B8C6BD-0D1C-43B6-80A3-C87BCA948539</gtr:id><gtr:title>Altering the ribosomal subunit ratio in yeast maximizes recombinant protein yield.</gtr:title><gtr:parentPublicationTitle>Microbial cell factories</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47a7e0c1a30cbdc3c9114d7bc4876109"><gtr:id>47a7e0c1a30cbdc3c9114d7bc4876109</gtr:id><gtr:otherNames>Bonander N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1475-2859</gtr:issn><gtr:outcomeId>doi_53d07b07b9c43f87</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>120E70BE-33CE-4F66-8080-10D6F2FEDD2C</gtr:id><gtr:title>Bioprocess optimisation and scale up of erythropoietin production in Pichia pastoris</gtr:title><gtr:parentPublicationTitle>Microbial Cell Factories</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99fa48557340fd583a51e1ca18bdd212"><gtr:id>99fa48557340fd583a51e1ca18bdd212</gtr:id><gtr:otherNames>N Bora</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>m_921959047113910d44</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">DT/F00270X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>